drugset
drugset / Trial / NCT03982225

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat

NCT03982225 ↗

Phase 2 Completed 143 enrolled AMIpharm Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 2 trial to evaluate the safety and potential efficacy of three concentration of polyene phosphatidylcholine injection (AYP-101) compared to placebo for the reduction of submental fat.

Timeline

Start
2019-07-01
Primary completion
2022-10-21
Completion
2022-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Polyene phosphatidylcholine injection Unknown 25 mg/ml Subcutaneous
Subject Polyene phosphatidylcholine injection Unknown 50 mg/ml Subcutaneous

Indications

No indication recorded.